Why the study?
Clopidogrel is routinely used to decrease ischemic complications during neurointerventional procedures, but its efficacy may be limited by antiplatelet resistance.
Does prasugrel reduce ischemic and hemorrhagic complications compared to clopidogrel in patients undergoing endovascular treatment of unruptured intracranial aneurysms?
Does prasugrel reduce ischemic and hemorrhagic complications compared to clopidogrel in patients undergoing endovascular treatment of unruptured intracranial aneurysms?
Low-dose prasugrel premedication is associated with a significant reduction in ischemic events and an acceptable rate of hemorrhagic complications compared to clopidogrel for endovascular treatment of unruptured intracranial aneurysms.
No takes yet. Share an insight, caveat, or question.
May support prasugrel consideration in neurointerventions; leaves open need for RCTs to confirm benefit and safety.
Cagnazzo et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: